Valneva

Equities

VLA

FR0004056851

Biotechnology & Medical Research

Market Closed - Euronext Paris Other stock markets 11:35:02 2024-07-17 EDT			5-day change	1st Jan Change
3.47 ^EUR	-0.69%		+3.46%	-26.48%

07-17	Pfizer Inc. and Valneva SE Announce Primary Vaccination Series Completion	CI
07-01	Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine	MT

Valneva SE Signs Research License Agreement with MSD Animal Health for Development of Vaccines in Eb66® Cell Line

January 05, 2017 at 01:21 am

Valneva SE announced that it has signed a research license agreement with MSD Animal Health, known as Merck Animal Health in the United States and Canada. The agreement grants MSD Animal Health the rights to research new vaccine candidates using Valneva's EB66® technology.

Latest news about Valneva

Pfizer Inc. and Valneva SE Announce Primary Vaccination Series Completion	07-17	CI
Valneva's Secures Marketing Authorization in Europe for Chikungunya Vaccine	07-01	MT
New semester, new state of mind	07-01
Valneva SE Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, Ixchiq	07-01	CI
Valneva: Marketing authorization granted to Ixchiq in Europe	07-01	CF
Valneva's Chikungunya Vaccine Secures Approval for Use in EU	06-28	MT
Valneva SE Appoints Daniele Guyot-Caparros as Board of Directors	06-26	CI
Valneva's Chikungunya Vaccine Receives Health Canada's Approval	06-24	MT
Valneva rises after Canadian approval for its chikungunya vaccine	06-24	RE
Valneva Secures Canadian Approval for Chikungunya Vaccine	06-24	MT
Europe opens hesitant as metal prices fall	06-24	RE
Valneva: Ixchiq approved in Canada	06-24	CF
Pfizer: article on Lyme vaccine in The Lancet	06-04	CF
Valneva: article on Lyme vaccine in The Lancet	06-04	CF
Valneva SE Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases	06-03	CI
Valneva: positive opinion from the CHMP in chikungunya	06-03	CF
Valneva's Chikungunya Vaccine Gains Support From EU Regulator Committee	05-31	MT
Valneva SE Receives EMA?s Positive CHMP Opinion for its Chikungunya Vaccine	05-31	CI
EU regulator recommends use of Valneva's chikungunya vaccine	05-31	RE
Valneva Se Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer	05-21	CI
Valneva Names New Chief Scientific Officer	05-21	MT
Valneva appoints Scientific Director	05-21	CF
Valneva: new positive data in CHIKV	05-13	CF
Valneva SE Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Transcript : Valneva SE, Q1 2024 Earnings Call, May 07, 2024	05-07

Chart Valneva

Duration

Period

More charts

Company Profile

Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. The group takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets two proprietary travel vaccines as well as certain third-party vaccines leveraging its established commercial infrastructure. Revenues from its growing commercial business help fuel the continued advancement of Valneva's vaccine pipeline. This includes the world's first vaccine against the chikungunya virus and the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release

Related indices

CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Ratings for Valneva

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.47 EUR

Average target price

8.633 EUR

Spread / Average Target

+148.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
VALNEVA	-26.48%	529M
MODERNA, INC.	+24.74%	47.96B
IQVIA HOLDINGS INC.	-0.47%	42.45B
LONZA GROUP AG	+43.96%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	31.6B
ICON PUBLIC LIMITED COMPANY	+17.96%	28.63B
CELLTRION, INC.	-4.47%	28.03B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.56B
MEDPACE HOLDINGS, INC.	+42.56%	14.14B
BIO-TECHNE CORPORATION	+1.46%	12.58B

Other Biotechnology & Medical Research